SouthState Corp’s ImmunityBio IBRX Stock Holding History

SouthState Corp’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,120	Closed	-$13.5K	–	1448
2025 Q2	$13.5K	Buy	+5,120	New	+$13.8K	﹤0.01%	724

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SouthState Corp's IBRX Position: Q3 2025 in Review

SouthState Corp sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 5,120 shares — an estimated $13.5K sold.

SouthState Corp first reported a position in IBRX in Q2 2025 and held it in 1 quarter. The position peaked at $13.5K in Q2 2025. 263 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

SouthState Corp reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
SouthState Corp sold 5,120 ImmunityBio shares in Q3 2025, an estimated $13.5K.
SouthState Corp first reported a position in ImmunityBio in Q2 2025 and held it in 1 quarter.
SouthState Corp's ImmunityBio position peaked at $13.5K in Q2 2025.
263 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.